ABMD | NASDAQ
Next Earnings: Jun 17, 2026
Company Overview:
10 Year ABMD Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
Get 3 months FREE!
ABMD Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for ABMD
Based on past 10-year performance, here are ABMD growth metrics:
Share price CAGR of +39.59%
Dividend CAGR of +0%
Using ABMD CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| ABMD (DRIP) | ABMD - No DRIP | |
|---|---|---|
| Current Price | $381.02 | $381.02 |
| Start Shares | 26.25 | 26.25 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 26.25 | 26.25 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $7,669.50 | $381.02 |
| Total Dividends | $0 | $0 |
| Final Value | $201,289 | $10,000 |
NOTE: Above numbers are our estimate based on ABMD's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Get 3 months FREE!
Company Info
Abiomed, Inc. (ABMD) had its IPO on 1987-07-29, and is trader on NASDAQ stock exchange.
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.
ABMD website: https://www.abiomed.com
Get Full Access to All Reports with DRIPCalc PRO
Get 3 months FREE!
